Author: Rather, Irfan A.; Choi, Sy-Bing; Kamli, Majid Rasool; Hakeem, Khalid Rehman; Sabir, Jamal S. M.; Park, Yong-Ha; Hor, Yan-Yan
Title: Potential Adjuvant Therapeutic Effect of Lactobacillus plantarum Probio-88 Postbiotics against SARS-COV-2 Cord-id: mt3clg85 Document date: 2021_9_24
ID: mt3clg85
Snippet: In response to the ongoing COVID-19 pandemic, the global effort to develop high efficacy countermeasures to control the infection are being conducted at full swing. While the efficacy of vaccines and coronavirus drugs are being tested, the microbiome approach represents an alternative pathophysiology-based approach to prevent the severity of the infection. In the current study, we evaluated the action of a novel probiotic Lactobacillus plantarum Probio-88 against SARS-COV-2 replication and immun
Document: In response to the ongoing COVID-19 pandemic, the global effort to develop high efficacy countermeasures to control the infection are being conducted at full swing. While the efficacy of vaccines and coronavirus drugs are being tested, the microbiome approach represents an alternative pathophysiology-based approach to prevent the severity of the infection. In the current study, we evaluated the action of a novel probiotic Lactobacillus plantarum Probio-88 against SARS-COV-2 replication and immune regulation using an in vitro and in silico study. The results showed that extract from this strain (P88-CFS) significantly inhibited the replication of SARS-COV-2 and the production of reactive oxygen species (ROS) levels. Furthermore, compared with infected cells, P88-CFS treated cells showed a significant reduction in inflammatory markers such as IFN-α, IFN-β, and IL-6. Using an in silico molecular docking approach, it was postulated that the antiviral activity of L. plantarum Probio-88 was derived from plantaricin E (PlnE) and F (PlnF). The high binding affinity and formation of hydrogen bonding indicated that the association of PlnE and PlnF on SARS-COV-2 helicase might serve as a blocker by preventing the binding of ss-RNA during the replication of the virus. In conclusion, our study substantiated that P88-CFS could be used as an integrative therapeutic approach along with vaccine to contain the spread of the highly infectious pathogen and possibly its variants.
Search related documents:
Co phrase search for related documents- adaptive innate and adjuvant therapy: 1, 2
- adaptive innate and live microorganism: 1
- adaptive innate and long history: 1
- adaptive innate and low grade inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- adaptive innate and lower expression: 1, 2, 3, 4, 5, 6
- adaptive innate and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- adaptive innate and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- adaptive innate and lung target organ: 1
- adaptive innate immune response and low grade inflammation: 1
- adaptive innate immune response and lung function: 1, 2, 3
- adaptive innate immune response and lung injury: 1, 2, 3, 4, 5, 6, 7
- adjuvant therapy and low grade inflammation: 1
- adjuvant therapy and lung function: 1, 2
- adjuvant therapy and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
- long history and lung function: 1, 2, 3, 4, 5
- long history and lung injury: 1, 2
- low grade inflammation and lung function: 1, 2, 3, 4, 5, 6
- lower expression and lung function: 1, 2, 3
- lower expression and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Co phrase search for related documents, hyperlinks ordered by date